Kwality Pharma Receives Product Registration for Bleomycin 15 IU in Mexico

Kwality Pharmaceutical Ltd has announced that it has received registration for Bleomycin 15 IU in Mexico for sale and distribution. Bleomycin is an effective anti-cancer medicine used in the treatment of Hodgkin’s lymphoma, testicular cancer, and certain squamous cell carcinomas. This approval strengthens Kwality Pharma's expansion into highly regulated markets and reinforces its commitment to delivering quality oncology products globally. The projected business potential is around 1 million USD in the first year, with supplies expected to commence before the end of Q2FY26.